Evaxion Biotech A/S investor relations material

Evaxion Biotech utilizes the AI platform, which is designed to reduce the identification of novel epitopes, and to develop neoantigens, vaccines, and antibody-based therapies; pNLS platform that is designed to identify novel protein structures through computational design; and 2D-to-3D structural similarity searching algorithm. It is developing EB023, a peptide based immunotherapy for the treatment of head and neck cancer. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.